FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Aldag Jorn					2. Issuer Name <b>and</b> Ticker or Trading Symbol HOOKIPA Pharma Inc. [ HOOK ]									tionship of all applica Director	Reporting Person(s) to Issuer lable)			
(Last) (First) (Middle) C/O HOOKIPA PHARMA INC.,					3. Date of Earliest Transaction (Month/Day/Year) 04/20/2020								X	Officer ( below)			1	
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240					4 If Amendment Data of Official Filed (Manth/Day)(Co.)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) NEW YORK NY 10118				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								ne) X	7 3 11				
(City)	(S	tate)	(Zip)															
		Ta	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, [	Disp	osed o	f, or Be	neficia	lly (	Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				e	Executio		Date,	Transaction Disposed		ities Acquired (A) o d Of (D) (Instr. 3, 4				s Forn llly (D) o ollowing (I) (Ir		Direct III	7. Nature of ndirect Beneficial Ownership Instr. 4)	
								Code	v	Amount	unt (A) or (D)			Transactio	tion(s)			1150.4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			B. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		epiration ate	Title	Amount or Number of Share	s		(Instr. 4)	J.1(J)		
Stock Option (Right to Buy)	\$8.03	04/20/2020		A		200,000		(1)	04	1/20/2030	Common Stock	200,00	0	\$0	0		D	

## **Explanation of Responses:**

1. 25% of this option shall vest on February 15, 2021, with the remainder vesting in 12 equal quarterly installments thereafter.

/s/ Reinhard Kandera, as 04/24/2020 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).